VCP
LGND icon

Verus Capital Partners’s Ligand Pharmaceuticals LGND Stock Holding History

Verus Capital Partners’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		$30K Sell
657
-313
-32% -$17.7K 0.01% 658
2019
Q4 		$63K Buy
+970
New +$64.8K 0.02% 523

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

Verus Capital Partners's LGND Position: Q1 2020 in Review

Verus Capital Partners reduced its Ligand Pharmaceuticals (LGND) stake by 32% in Q1 2020, selling an estimated $17.7K and leaving 657 shares worth $30K. The position accounts for 0.01% of the portfolio, ranked #658.

Verus Capital Partners first reported a position in LGND in Q4 2019 and has held it in 2 quarters since. The position peaked at $63K in Q4 2019. 262 funds tracked by Wall St. Rank hold LGND as of Q1 2020.

  • Verus Capital Partners held 657 shares of Ligand Pharmaceuticals worth $30K as of Q1 2020.
  • Verus Capital Partners sold 313 Ligand Pharmaceuticals shares in Q1 2020, an estimated $17.7K.
  • Ligand Pharmaceuticals made up 0.01% of Verus Capital Partners's portfolio in Q1 2020, its #658 holding.
  • Verus Capital Partners first reported a position in Ligand Pharmaceuticals in Q4 2019 and has held it in 2 quarters since.
  • Verus Capital Partners's Ligand Pharmaceuticals position peaked at $63K in Q4 2019.
  • 262 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2020.

Based on Verus Capital Partners's 13F filing for Q1 2020, filed 26 May 2020.